A Novel Tumor Glycolysis Inhibitor: 4-Methylumbelliferone
Zi-Yao Li1, Qin Yang1, Xiao-Ge Cheng1, Yan-Li Zhou1, Xiang-Ling Piao1, Li Qiu1, Bo-Jun Zhou1, Song-Tao Wu1★★ Corresponding author
- 1Faculty of Pharmacy, Hubei University of Chinese Medicine, Wuhan, CHINA.
- 2Key Laboratory of Traditional Chinese Medicine Resources and Chemistry of Hubei Province, Wuhan, China.
CORRESPONDENCE
Song-Tao Wu
Faculty of Pharmacy, Hubei University of Chinese Medicine, Wuhan, CHINA.
Received: 07-03-2023; Accepted: 06-09-2023.
Volume 20, Issue 1 · pp. 230–244 · PUBLISHED 2024 · DOI: 10.1177/09731296231206300
View on Pharmacogn. Mag. original site ↗
ABSTRACT
Background and Objectives: 4-Methylumbelliferone (4-MU) is a coumarin compound that can be extracted from the medicinal plant with anti-cancer properties, Smilax china L. In recent years, studies have revealed its potential as an antitumor and anti-metastasis drug with promising effects in cancer treatment. Despite an increase in research on the metabolic patterns of tumor cells, no prior research has suggested that 4-MU inhibits tumor proliferation by blocking glycolysis. This thesis presents evidence that 4-MU binds to proteins involved in glycolysis, thus mediating its anti-tumor effects. Materials and Methods: Network pharmacology, transcriptomics, and molecular docking were utilized to forecast the potential targets and probable pathways of 4-MU’s anti-cancer activity, and the affinity of 4-MU towards potential targets was discovered using microscale thermophoresis (MST) detection. Results: The results of transcriptome analysis brought to light that the genes with differential expressions were primarily enriched in metabolic pathways, including glycolysis-related proteins. Using network pharmacology and molecular docking, our study identified Heat Shock Protein 90 Alpha Family Class A Member 1 (Hsp90AA1), mitochondria, phosphoglycerate kinase 2 (PGK2), glycerol-3-phosphate dehydrogenase (GPD2), and glucose-6-phosphate isomerase (GPI) as potential targets of 4-MU. The strong binding affinity between 4-MU and these proteins was confirmed by the MST assay. Conclusion: The findings indicate that 4-MU can hinder glycolysis by binding to glycolysis-associated proteins such as Hsp90AA1, PGK2, GPD2, and GPI. This results in the prevention of the energy supply to the tumor tissue, which ultimately curbs tumor growth, thereby demonstrating its anti-tumor properties. These results conclude that 4-MU has the capacity to be a novel glycolysis inhibitor for cancer treatment. Moreover, the identification of these glycolysis-associated proteins as possible targets for cancer therapy offers new avenues for research in the field of cancer treatment, thus providing further valuable evidence for the anti-cancer mechanism of 4-MU.
KEYWORDS
REFERENCES
As publishedShowing references and in-text citations exactly as published.
Cite this article
SELECT FORMAT
Li, Z., Yang, Q., Cheng, X., Zhou, Y., Piao, X., Qiu, L., Zhou, B., & Wu, S. (2024). A Novel Tumor Glycolysis Inhibitor: 4-Methylumbelliferone. Pharmacognosy Magazine, 20(1), 230–244. https://doi.org/10.1177/09731296231206300